Ataciguat is under clinical development by Rancho Santa Fe Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ataciguat’s likelihood of approval (LoA) and phase transition for Aortic Valve Stenosis took place on 22 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 22 Jun 2021 decreased Ataciguat’s LoA and PTSR for Cardiac Valve Calcification.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ataciguat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ataciguat overview

Ataciguat (HMR1766) is under development for the treatment of aortic valve calcification in patients with moderate calcific aortic valve stenosis. Ataciguat is administered orally as a capsule. Ataciguat targets guanylate cyclase. It is an anthranilic acid derivative, belonging to a structural class of sGC activators capable of activating the oxidized form of sGC. It was also under development for the treatment of neuropathic pain and intermittent claudication in peripheral arterial disease.

Rancho Santa Fe Bio overview

Rancho Santa Fe Bio, Inc. (RSF Bio) is a clinical-stage cardiovascular platform company. RSF Bio is headquartered in the US.

Quick View Ataciguat LOA Data

Report Segments
  • Innovator
Drug Name
  • Ataciguat
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.